Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats
- 1 January 2010
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 20 (1) , 37-48
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in ratsPsychopharmacology, 2008
- Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational studyPsychopharmacology, 2008
- Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: Impact of distractorsSchizophrenia Research, 2007
- Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses that Enhance Cognitive FunctionBiological Psychiatry, 2006
- Prefrontal Electrophysiologic “Noise” and Catechol-O-Methyltransferase Genotype in SchizophreniaBiological Psychiatry, 2006
- Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and miceEuropean Neuropsychopharmacology, 2006
- Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capabilityNeuroscience, 2006
- Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteersSchizophrenia Research, 2005
- Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophreniaPsychopharmacology, 2005
- 5-HT 3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the ratPsychopharmacology, 2002